Aroa Biosurgery Ltd
ASX:ARX

Watchlist Manager
Aroa Biosurgery Ltd Logo
Aroa Biosurgery Ltd
ASX:ARX
Watchlist
Price: 0.74 AUD 8.82%
Market Cap: 255.2m AUD
Have any thoughts about
Aroa Biosurgery Ltd?
Write Note

Net Margin
Aroa Biosurgery Ltd

-10%
Current
-14%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-10%
=
Net Income
-7.6m
/
Revenue
76.4m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
NZ
Aroa Biosurgery Ltd
ASX:ARX
255.2m AUD
-10%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
318.1B USD
9%
US
Amgen Inc
NASDAQ:AMGN
142.2B USD
13%
US
Gilead Sciences Inc
NASDAQ:GILD
117.1B USD
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.2B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
135.7B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36.2B EUR
-14%
Country NZ
Market Cap 255.2m AUD
Net Margin
-10%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 318.1B USD
Net Margin
9%
Country US
Market Cap 142.2B USD
Net Margin
13%
Country US
Market Cap 117.1B USD
Net Margin
0%
Country US
Market Cap 105.2B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 135.7B AUD
Net Margin
18%
Country US
Market Cap 78.7B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 36.2B EUR
Net Margin
-14%
No Stocks Found

Aroa Biosurgery Ltd
Glance View

Market Cap
255.2m AUD
Industry
Biotechnology

Aroa Biosurgery Ltd. engages in the development of products for wound care and soft tissue regeneration. The firm is engaged in commercializing regenerative tissue substitutes for medical conditions where impaired healing leads to serious consequences for patients. The company designs and manufactures medical products which enable surgeons and clinicians to repair serious tissue injuries. The Company’s solutions include Endoform platform, Wound Care Portfolio and Reinforced Bioscaffolds. The Endoform platform is a building block for developing a range of regenerative tissue substitutes to assist with tissue repair and healing. Its wound care products comprise extracellular matrix to manage acute and chronic wounds. The Reinforced Bioscaffolds combine the biologics and synthetics to address the surgical ventral hernia repair solutions.

ARX Intrinsic Value
1.18 AUD
Undervaluation 38%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-10%
=
Net Income
-7.6m
/
Revenue
76.4m
What is the Net Margin of Aroa Biosurgery Ltd?

Based on Aroa Biosurgery Ltd's most recent financial statements, the company has Net Margin of -10%.